血清和滑液趋化因子配体2/单核细胞趋化蛋白1浓度与膝骨关节炎患者的症状严重程度相关。
Serum and synovial fluid chemokine ligand 2/monocyte chemoattractant protein 1 concentrations correlates with symptomatic severity in patients with knee osteoarthritis.
作者信息
Li Liang, Jiang Bao-En
机构信息
Dong Ying People's Hospital, Dong Ying, China
Dong Ying People's Hospital, Dong Ying, China.
出版信息
Ann Clin Biochem. 2015 Mar;52(Pt 2):276-82. doi: 10.1177/0004563214545117. Epub 2014 Jul 8.
OBJECTIVE
Serum and synovial fluid (SF) chemokine ligand 2 (CCL2)/monocyte chemoattractant protein 1 (MCP-1) concentrations have been identified to be increased in osteoarthritis (OA) patients. The scope of this study was to examine CCL2 concentrations in serum and SF of knee OA patients and to explore their association with patient-reported symptomatic severity.
METHOD
One hundred and sixty-one knee OA patients and 138 healthy controls were enrolled into the study from our hospital. We collected Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores from OA patients and measured CCL2 concentrations in serum and SF using enzyme-linked immunosorbent assay method, and correlation between WOMAC scores and CCL2 concentrations were analysed.
RESULTS
CCL2 concentrations in SF instead of serum were independently and positively associated with self-reported greater pain (r = 0.460, P < 0.001) and physical disability (r = 0.561, P < 0.001) in OA patients.
CONCLUSION
CCL2 in SF might serve as a novel and reliable biomarker for assessing symptomatic severity of OA.
目的
已确定骨关节炎（OA）患者血清和滑液（SF）中的趋化因子配体2（CCL2）/单核细胞趋化蛋白1（MCP-1）浓度升高。本研究旨在检测膝骨关节炎患者血清和滑液中的CCL2浓度，并探讨其与患者报告的症状严重程度之间的关联。
方法
从我院招募了161例膝骨关节炎患者和138例健康对照者。我们收集了骨关节炎患者的西安大略和麦克马斯特大学关节炎指数（WOMAC）评分，并采用酶联免疫吸附测定法测量血清和滑液中的CCL2浓度，分析WOMAC评分与CCL2浓度之间的相关性。
结果
在骨关节炎患者中，滑液而非血清中的CCL2浓度与自我报告的更严重疼痛（r = 0.460，P < 0.001）和身体残疾（r = 0.561，P < 0.001）独立正相关。
结论
滑液中的CCL2可能作为评估骨关节炎症状严重程度的一种新的可靠生物标志物。
Zotero 插件